Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Market price (% of par)
-
100.0%
-
Total 13F principal
-
$378,633,300
-
Principal change
-
+$24,213,000
-
Total reported market value
-
$378,218,157
-
Number of holders
-
48
-
Value change
-
+$23,476,834
-
Number of buys
-
14
-
Number of sells
-
19
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q1 2022
As of 31 Mar 2022,
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 was held by
48 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$378,633,300
in principal (par value) of the bond.
The largest 10 bondholders included
PFM Health Sciences, LP, Allianz Asset Management GmbH, ADVENT CAPITAL MANAGEMENT /DE/, ROYAL BANK OF CANADA, SHENKMAN CAPITAL MANAGEMENT INC, MORGAN STANLEY, PALISADE CAPITAL MANAGEMENT LLC/NJ, SCHRODER INVESTMENT MANAGEMENT GROUP, BlackRock Inc., and Thrivent Financial for Lutherans.
This page lists
48
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.